Eikon Therapeutics Stock

eikontx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $1.21B

Eikon Therapeutics is a drug discovery and development business focused on the movements of single proteins within cells. Eikon's proprietary microscopes can visualize the movement within these cells. Eikon Therapeutics was founded in 2019 by Luke Lavis, Robert Tjian Ph.D., Xavier Darzacq Ph.D., and Eric Betzig and is headquartered in Hayward, CA.

Register for Details

For more details on financing and valuation for Eikon Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Eikon Therapeutics.

Register Today


Management Team

Roger Perlmutter
President, Chief Executive Officer & Chairman
Alfred Bowie Ph.D
Chief Financial Officer
Russ Berman
Chief Technology Officer
Ashish Kheterpal
Chief Information Officer
Daniel Anderson Ph.D
Chief Scientific Officer
Benjamin Thorner JD
Chief Business Officer & General Counsel
Roy Baynes Ph.D
Chief Medical Officer & Executive Vice President

Board Members

James Tananbaum MD
Foresite Capital Management
Joshua Wolfe
Lux Capital

Other companies like Eikon Therapeutics in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Eikon snaps up clinical pipeline thanks to 'buyer's market,' while internal pipeline remains covert
Eikon Therapeutics emerged with the promise of Nobel Prize-winning molecule tracking technology. But now, CEO Roger Perlmutter, M.D., Ph.D., and co. are using their more than $600 million war chest for something else: buying up clinical-stage drugs.
Eikon Acquires Broad Development Pipeline, Raises $106M in Series C Funding
Led by biopharma titan Roger Perlmutter, Eikon Therapeutics kicked off 2022 with a Series B financing worth $517.8 million. The Bay Area-based biotech made another splash Thursday, announcing a $106 million Series C raise and the acquisition of exclusive, global rights to several early- to mid-stage assets.
Biotech company Eikon Therapeutics to open New York City operations base
Eikon Therapeutics, a drug discovery and development company, has signed a lease to open a New York City operations base at the Alexandria Center for Life Science at 430 E. 29th St.
Updated on: Sep 29, 2023